TYPTF (Entropy Neurodynamics) Total Liabilities: $0.75 Mil (As of Dec. 2025)


What is Entropy Neurodynamics Total Liabilities?

Entropy Neurodynamics TYPTF -45.63% Total Liabilities is $0.75 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Entropy Neurodynamics's Total Liabilities for the quarter that ended in Dec. 2025 was $0.75 Mil.

Entropy Neurodynamics's quarterly Total Liabilities declined from Dec. 2024 ($0.67 Mil) to Jun. 2025 ($0.46 Mil) but then increased from Jun. 2025 ($0.46 Mil) to Dec. 2025 ($0.75 Mil).

Entropy Neurodynamics's annual Total Liabilities declined from Jun. 2022 ($3.38 Mil) to Jun. 2023 ($1.18 Mil) and declined from Jun. 2023 ($1.18 Mil) to Jun. 2025 ($0.46 Mil).

Entropy Neurodynamics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics Total Liabilities Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
Total Liabilities
Get a 7-Day Free Trial 1.05 1.98 3.38 1.18 0.46

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 0.25 0.67 0.46 0.75

Entropy Neurodynamics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Entropy Neurodynamics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.455+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.46

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=4.338-3.883
=0.46

Entropy Neurodynamics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.749+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.75

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=6.03-5.281
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.75 Mil mean?
Entropy Neurodynamics (TYPTF) has a Total Liabilities of $0.75 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Total Liabilities too high?
Entropy Neurodynamics' current Total Liabilities is $0.75 Mil.
How does Entropy Neurodynamics' Total Liabilities compare to VRTX and REGN?
Entropy Neurodynamics' Total Liabilities of $0.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Total Liabilities is $0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current Total Liabilities is $0.75 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Total Liabilities is $0.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges ENP:Australia
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.